Download PDF
Fortschr Neurol Psychiatr 2014; 82(4): 191-202
DOI: 10.1055/s-0034-1366193
Übersicht
© Georg Thieme Verlag KG Stuttgart · New York

12 Jahre Kompetenznetz Schizophrenie: Ergebnisse und Perspektiven

12 Years of Competence Network Schizophrenia: Results and Perspectives
W. Gaebel
1   Klinik und Poliklinik für Psychiatrie und Psychotherapie, Medizinische Fakultät, Heinrich-Heine-Universität Düsseldorf
,
G. Buchkremer
2   Klinik für Psychiatrie und Psychotherapie, Universität Tübingen
,
H. Häfner
3   Arbeitsgruppe Schizophrenieforschung, Zentralinstitut für Seelische Gesundheit Mannheim
,
J. Klosterkötter
4   Klinik für Psychiatrie und Psychotherapie, Universität Köln
,
W. Maier
5   Klinik für Psychiatrie und Psychotherapie, Universität Bonn
,
W. Wölwer
1   Klinik und Poliklinik für Psychiatrie und Psychotherapie, Medizinische Fakultät, Heinrich-Heine-Universität Düsseldorf
› Author Affiliations
Further Information

Publication History

14 January 2014

16 February 2014

Publication Date:
07 April 2014 (online)

Also available at
    Permissions and Reprints

Zusammenfassaung

Das Kompetenznetz Schizophrenie (KNS) wurde von 1999 bis 2011 vom Bundesministerium für Bildung und Forschung (BMBF) gefördert. Ziele und Struktur des Netzwerks mit horizontaler und vertikaler Vernetzung deutscher Forschungs- und Versorgungseinrichtungen dienten der wissenschaftlichen Bearbeitung offener Forschungsfragen zur Schizophrenie und der klinisch-praktischen Umsetzung von deren Ergebnissen. Im vorliegenden Beitrag werden Arbeitsweise und Ergebnisse des KNS anhand ausgewählter Forschungsprojekte dargestellt. Quantitative und qualitative Bewertungsparameter wie wissenschaftliche Publikationen und zusätzliche Drittmitteleinwerbung durch Folgeförderung sowie Nachwuchsförderung, Öffentlichkeitsarbeit, Kongressaktivitäten und Gründung einer europäischen Schizophreniegesellschaft belegen die erfolgreiche Arbeit des Netzwerks. Abschließend wird der Förderschwerpunkt des BMBF am Beispiel des KNS kritisch bewertet und künftige Förderperspektiven werden skizziert.

Abstract

The German Research Network on Schizophrenia (GRNS) was funded by the Federal Ministry of Education and Research (BMBF) from 1999 to 2011. The objectives and the structure of the network with its horizontal and vertical networking of German research and care facilities served for the scientific investigation of open research questions for schizophrenia, and the transfer of the results into clinical practice. In this paper, the functioning and results of the GRNS are described on the basis of selected research projects. Quantitative and qualitative evaluation parameters such as scientific publications and additional external funds, as well as promotion of young scientists, public relations activities, congress activities and foundation of an European Schizophrenia Association demonstrate the successful work of the network. As a final point, the funding programme of the BMBF is critically evaluated using the example of the GRNS and future funding prospects are outlined.

Schlüsselwörter

Schizophrenie - Kompetenznetz - Forschung - Versorgung - Förderprogramm

Key words

schizophrenia - competence network - research - health-care - funding programmes
 

  • Literatur

  • 1 Wölwer W, Buchkremer G, Häfner H et al. German research network on schizophrenia-bridging the gap between research and care. Eur Arch Psychiatry Clin Neurosci 2003; 253: 321-329
    CrossrefPubMedGoogle Scholar
  • 2 Schaffner N, Schimmelmann BG, Niedersteberg A et al. Versorgungswege von erstmanifesten psychotischen Patienten – eine Übersicht internationaler Studien. Fortschr Neurol Psychiatr 2011; 80: 72-78
    Article in Thieme ConnectPubMedGoogle Scholar
  • 3 Marshall M, Lewis S, Lockwood A et al. Association between duration of untreated psychosis and outcome in cohorts of first-episode patients: a systematic review. Arch Gen Psychiatry 2005; 62: 975-983
    Google Scholar
  • 4 Sahlmann MM, Vieten AB, Sheldrick AJ et al. Früherkennung und Frühbehandlung bei Patienten mit erhöhtem Schizophrenierisiko in Deutschland. Gesundheitswesen 2010; 72: 771-775
    Google Scholar
  • 5 Häfner H, Maurer K, Ruhrmann S et al. Early detection and secondary prevention of psychosis: facts and visions. Eur Arch Psychiatry Clin Neurosci 2004; 254: 117-128
    CrossrefPubMedGoogle Scholar
  • 6 Klosterkötter J, Hellmich M, Steinmeyer EM et al. Diagnosing schizophrenia in the initial prodromal phase. Arch Gen Psychiatry 2001; 58: 158-164
    Google Scholar
  • 7 Bechdolf A, Ruhrmann S, Wagner M et al. Interventions in the initial prodromal states of psychosis in Germany: concept and recruitment. Br J Psychiatry Suppl 2005; 48: s45-s48
    PubMedGoogle Scholar
  • 8 Bechdolf A, Wagner M, Ruhrmann S et al. Preventing progression to first-episode psychosis in early initial prodromal states. Br J Psychiatry 2012; 200: 22-29
    CrossrefPubMedGoogle Scholar
  • 9 Ruhrmann S, Bechdolf A, Kuhn KU et al. Acute effects of treatment for prodromal symptoms for people putatively in a late initial prodromal state of psychosis. Br J Psychiatry Suppl 2007; 51: s88-s95
    PubMedGoogle Scholar
  • 10 Ruhrmann S, Schultze-Lutter F, Salokangas RK et al. Prediction of psychosis in adolescents and young adults at high risk: results from the prospective European prediction of psychosis study. Arch Gen Psychiatry 2010; 67: 241-251
    Google Scholar
  • 11 Bechdolf A, Muller H, Stutzer H et al. Rationale and baseline characteristics of PREVENT: a second-generation intervention trial in subjects at-risk (prodromal) of developing first-episode psychosis evaluating cognitive behavior therapy, aripiprazole, and placebo for the prevention of psychosis. Schizophr Bull 2011; 37 (Suppl. 02) S111-S121
    CrossrefPubMedGoogle Scholar
  • 12 Leucht S, Barnes TR, Kissling W et al. Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. Am J Psychiatry 2003; 160: 1209-1222
    Google Scholar
  • 13 Geddes J, Freemantle N, Harrison P et al. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. Bmj 2000; 321: 1371-1376
    CrossrefPubMedGoogle Scholar
  • 14 Marder SR, Essock SM, Miller AL et al. The Mount Sinai conference on the pharmacotherapy of schizophrenia. Schizophr Bull 2002; 28: 5-16
    CrossrefPubMedGoogle Scholar
  • 15 Kane JM, Leucht S, Carpenter D et al. The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary. J Clin Psychiatry 2003; 64 (Suppl. 12) 5-19
    CrossrefPubMedGoogle Scholar
  • 16 National Institute for Clinical Excellence (NICE). Guidance on the Use of Newer (Atypical) Antipsychotic Drugs for the Treatment of Schizophrenia. Technology Appraisal Guidance 2002; 43
    PubMedGoogle Scholar
  • 17 Stroup TS, McEvoy JP, Swartz MS et al. The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development. Schizophr Bull 2003; 29: 15-31
    CrossrefPubMedGoogle Scholar
  • 18 Fleischhacker WW, Keet IP, Kahn RS. The European First Episode Schizophrenia Trial (EUFEST): rationale and design of the trial. Schizophr Res 2005; 78: 147-156
    CrossrefPubMedGoogle Scholar
  • 19 Jones PB, Barnes TR, Davies L et al. Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry 2006; 63: 1079-1087
    CrossrefPubMedGoogle Scholar
  • 20 American Psychiatric Association. Practice Guideline for the Treatment of Patients with Schizophrenia. Amer Psychiatric Pub Inc 1997;
    PubMedGoogle Scholar
  • 21 Deutsche Gesellschaft für Psychiatrie, Psychotherapie und Nervenheilkunde (DGPPN). Praxisleitlinien in Psychiatrie und Psychotherapie. Darmstadt: Steinkopff; 2005. 1998
    Google Scholar
  • 22 Gaebel W, Möller HJ, Buchkremer G et al. Pharmacological long-term treatment strategies in first episode schizophrenia--study design and preliminary results of an ongoing RCT within the German Research Network on Schizophrenia. Eur Arch Psychiatry Clin Neurosci 2004; 254: 129-140
    CrossrefPubMedGoogle Scholar
  • 23 Gaebel W, Riesbeck M, Wölwer W et al. Maintenance treatment with risperidone or low-dose haloperidol in first-episode schizophrenia: 1-year results of a randomized controlled trial within the German Research Network on Schizophrenia. J Clin Psychiatry 2007; 68: 1763-1774
    Google Scholar
  • 24 Gaebel W, Riesbeck M, Wölwer W et al. Relapse prevention in first-episode schizophrenia--maintenance vs intermittent drug treatment with prodrome-based early intervention: results of a randomized controlled trial within the German Research Network on Schizophrenia. J Clin Psychiatry 2011; 72: 205-218
    CrossrefPubMedGoogle Scholar
  • 25 Wölwer W, Toeller V, Klingberg S et al. Spezialisierte Behandlungsangebote für erstmals schizophren Erkrankte: Konzepte und Ergebnisse. Fortschr Neurol Psychiatr 2012; 81: 276-283
    Article in Thieme ConnectPubMedGoogle Scholar
  • 26 Kirkpatrick B, Fenton WS, Carpenter Jr WT et al. The NIMH-MATRICS consensus statement on negative symptoms. Schizophr Bull 2006; 32: 214-219
    CrossrefPubMedGoogle Scholar
  • 27 Buchanan RW. Persistent negative symptoms in schizophrenia: an overview. Schizophr Bull 2007; 33: 1013-1022
    CrossrefPubMedGoogle Scholar
  • 28 Leucht S, Corves C, Arbter D et al. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009; 373: 31-41
    Google Scholar
  • 29 Correll CU. From receptor pharmacology to improved outcomes: individualising the selection, dosing, and switching of antipsychotics. Eur Psychiatry 2010; 25 (Suppl. 02) S12-S21
    CrossrefPubMedGoogle Scholar
  • 30 Le Francois B, Czesak M, Steubl D et al. Transcriptional regulation at a HTR1A polymorphism associated with mental illness. Neuropharmacology 2008; 55: 977-985
    CrossrefPubMedGoogle Scholar
  • 31 Drago A, Ronchi DD, Serretti A. 5-HT1A gene variants and psychiatric disorders: a review of current literature and selection of SNPs for future studies. Int J Neuropsychopharmacol 2008; 11: 701-721
    PubMedGoogle Scholar
  • 32 Mössner R, Schuhmacher A, Kuhn KU et al. Functional serotonin 1A receptor variant influences treatment response to atypical antipsychotics in schizophrenia. Pharmacogenet Genomics 2009; 19: 91-94
    Google Scholar
  • 33 Mössner R, Schuhmacher A, Wagner M et al. DAOA/G72 predicts the progression of prodromal syndromes to first episode psychosis. Eur Arch Psychiatry Clin Neurosci 2010; 260: 209-215
    CrossrefPubMedGoogle Scholar
  • 34 Gmür M, Tschopp A. Die Behandlungskontinuität bei schizophrenen Patienten in der Ambulanz. Eine 5-Jahres Untersuchung. Nervenarzt 1998; 59: 727-730
    PubMedGoogle Scholar
  • 35 Lehman AF, Steinwachs DM. Translating research into practice: the Schizophrenia Patient Outcomes Research Team (PORT) treatment recommendations. Schizophr Bull 1998; 24: 1-10
    CrossrefPubMedGoogle Scholar
  • 36 Janssen B, Weinmann S, Berger M et al. Leitlinienkonformität und Behandlungsergebnisse in der stationären Schizophreniebehandlung. Ein Klinikvergleich. Nervenarzt 2005; 76: 315-326
    CrossrefPubMedGoogle Scholar
  • 37 Janssen B, Ludwig S, Eustermann H et al. Improving outpatient treatment in schizophrenia: effects of computerized guideline implementation–results of a multicenter-study within the German Research Network on Schizophrenia. European Archives of Psychiatry and Clinical Neuroscience 2010; 260: 51-57
    CrossrefPubMedGoogle Scholar
  • 38 Janssen B, van Brederode M, Kitzig F et al. Benchmarking in psychiatric acute care--a demonstration project in a hospitals network. Z Evid Fortbild Qual Gesundhwes 2011; 105: 371-375
    CrossrefPubMedGoogle Scholar
  • 39 Grossimlinghaus I, Falkai P, Gaebel W et al. Developmental process of DGPPN quality indicators. Nervenarzt 2013; 84: 350-365
    CrossrefPubMedGoogle Scholar
  • 40 Schmidt-Kraepelin C, Janssen B, Gaebel W. Prevention of rehospitalization in schizophrenia: results of an integrated care project in Germany. European Archives of Psychiatry and Clinical Neuroscience 2009; 259: 205-212
    CrossrefPubMedGoogle Scholar
  • 41 WPA. Global Programme Against Stigma and Discrimination Because of Schizophrenia. Chicago III: Closer Look Creative, Inc; USA 1999
    Google Scholar
  • 42 Gaebel W, Baumann AE. Interventions to reduce the stigma associated with severe mental illness: experiences from the open the doors program in Germany. Can J Psychiatry 2003; 48: 657-662
    PubMedGoogle Scholar
  • 43 Gaebel W, Baumann A, Witte AM et al. Public attitudes towards people with mental illness in six German cities: results of a public survey under special consideration of schizophrenia. Eur Arch Psychiatry Clin Neurosci 2002; 252: 278-287
    CrossrefPubMedGoogle Scholar
  • 44 Baumann A, Zäske H, Decker P et al. Veränderungen in der sozialen Distanz der Bevölkerung gegenüber schizophren Erkrankten in 6 deutschen Großstädten. Ergebnisse einer repräsentativen Telefonbefragung 2001 und 2004. Nervenarzt 2007; 78: 787-788 , 790–785
    CrossrefPubMedGoogle Scholar
  • 45 Pinfold V, Thornicroft G, Huxley P et al. Active ingredients in anti-stigma programmes in mental health. Int Rev Psychiatry 2005; 17: 123-131
    CrossrefPubMedGoogle Scholar
  • 46 Freimüller L, Wölwer W. Antistigma-Kompetenz in der psychiatrisch-psychotherapeutischen und psychosozialen Praxis. Stuttgart: Schattauer; 2012
    CrossrefGoogle Scholar
  • 47 Gaebel W, Zäske H, Baumann AE et al. Evaluation of the German WPA „program against stigma and discrimination because of schizophrenia–Open the Doors“: results from representative telephone surveys before and after three years of antistigma interventions. Schizophr Res 2008; 98: 184-193
    PubMedGoogle Scholar
  • 48 Angermeyer MC, Matschinger H, Carta MG et al. Changes in the perception of mental illness stigma in Germany over the last two decades. Eur Psychiatry 2013;
    PubMedGoogle Scholar
  • 49 Klingberg S, Schaub A, Conradt B. Rezidivprophylaxe bei schizophrenen Störungen – Ein kognitiv-verhaltenstherapeutisches Behandlungsmanual. Weinheim: BeltzPVU; 2003
    Google Scholar
  • 50 Bechdolf A, Pützfeld V, Güttgemanns J et al. Kognitive Verhaltenstherapie bei Personen mit erhöhtem Psychoserisiko – Ein Behandlungsmanual. Bern: Huber; 2010
    Google Scholar
  • 51 Häfner H, Bechdolf A, Klosterkötter J et al. Psychosen – Früherkennung und Frühintervention. Stuttgart: Schattauer; 2012
    Google Scholar
  • 52 Wölwer W, Frommann N, Halfmann S et al. Remediation of impairments in facial affect recognition in schizophrenia: efficacy and specificity of a new training program. Schizophr Res 2005; 80: 295-303
    CrossrefPubMedGoogle Scholar
  • 53 Klingberg S, Wittorf A, Meisner C et al. Cognitive behavioural therapy versus supportive therapy for persistent positive symptoms in psychotic disorders: the POSITIVE Study, a multicenter, prospective, single-blind, randomised controlled clinical trial. Trials 2010; 11: 123
    CrossrefPubMedGoogle Scholar
  • 54 Klingberg S, Wölwer W, Engel C et al. Negative symptoms of schizophrenia as primary target of cognitive behavioral therapy: results of the randomized clinical TONES study. Schizophr Bull 2011; 37 (Suppl. 02) S98-S110
    CrossrefPubMedGoogle Scholar
  • 55 Cordes J, Falkai P, Guse B et al. Repetitive transcranial magnetic stimulation for the treatment of negative symptoms in residual schizophrenia: rationale and design of a sham-controlled, randomized multicenter study. Eur Arch Psychiatry Clin Neurosci 2009; 259 (Suppl. 02) S189-S197
    CrossrefPubMedGoogle Scholar
  • 56 Puschner B, Steffen S, Volker KA et al. Needs-oriented discharge planning for high utilisers of psychiatric services: multicentre randomised controlled trial. Epidemiol Psychiatr Sci 2011; 20: 181-192
    CrossrefPubMedGoogle Scholar
  • 57 Hamann J, Cohen R, Leucht S et al. Shared decision making and long-term outcome in schizophrenia treatment. J Clin Psychiatry 2007; 68: 992-997
    CrossrefPubMedGoogle Scholar
  • 58 Hasan A, Wobrock T, Grefkes C et al. Deficient inhibitory cortical networks in antipsychotic-naive subjects at risk of developing first-episode psychosis and first-episode schizophrenia patients: a cross-sectional study. Biol Psychiatry 2012; 72: 744-751
    CrossrefPubMedGoogle Scholar
  • 59 Nenadic I, Yotter RA, Sauer H et al. Cortical surface complexity in frontal and temporal areas varies across subgroups of schizophrenia. Hum Brain Mapp 2013;
    PubMedGoogle Scholar
  • 60 Wittorf A, Wiedemann G, Buchkremer G et al. Prediction of community outcome in schizophrenia 1 year after discharge from inpatient treatment. Eur Arch Psychiatry Clin Neurosci 2008; 258: 48-58
    CrossrefPubMedGoogle Scholar
  • 61 Quednow BB, Frommann I, Berning J et al. Impaired sensorimotor gating of the acoustic startle response in the prodrome of schizophrenia. Biol Psychiatry 2008; 64: 766-773
    CrossrefPubMedGoogle Scholar
  • 62 Bodatsch M, Ruhrmann S, Wagner M et al. Prediction of psychosis by mismatch negativity. Biol Psychiatry 2011; 69: 959-966
    CrossrefPubMedGoogle Scholar
  • 63 Koutsouleris N, Borgwardt S, Meisenzahl EM et al. Disease prediction in the at-risk mental state for psychosis using neuroanatomical biomarkers: results from the FePsy study. Schizophr Bull 2012; 38: 1234-1246
    CrossrefPubMedGoogle Scholar